| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ANCCA; Atad2; CT137; L16; PRO2000;;ATAD2 |
| WB Predicted band size | Calculated MW: 159 kDa ; Observed MW: 180 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human ATAD2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于ATAD2抗体的代表性文献摘要简述：
---
1. **文献名称**: "ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors"
**作者**: Ciro et al.
**摘要**: 研究利用ATAD2特异性抗体(兔多克隆)通过免疫组化(IHC)和免疫印迹(Western blot)发现，ATAD2在多种癌症(如乳腺癌、肺癌)中高表达，并与MYC协同促进肿瘤细胞增殖。抗体验证显示其特异性结合ATAD2的ATP酶结构域。
2. **文献名称**: "ATAD2 as a biomarker for poor prognosis in hepatocellular carcinoma"
**作者**: Zheng et al.
**摘要**: 通过ATAD2单克隆抗体(小鼠来源)对肝癌组织进行免疫组化分析，发现ATAD2高表达与患者生存期缩短显著相关。抗体特异性通过siRNA敲低实验验证，提示其可作为肝癌预后标志物。
3. **文献名称**: "ATAD2 interacts with CBP/p300 to regulate transcription and promote prostate cancer progression"
**作者**: Hu et al.
**摘要**: 使用ATAD2抗体(兔源，ChIP级别)进行染色质免疫沉淀(ChIP)和免疫荧光(IF)，揭示ATAD2通过结合组蛋白乙酰转移酶CBP/p300调控雄激素受体(AR)靶基因转录，促进前列腺癌转移。抗体特异性通过敲除细胞系验证。
---
这些文献展示了ATAD2抗体在机制研究(如蛋白互作、转录调控)及临床诊断(如生物标志物筛选)中的关键应用。如需具体DOI或补充文献，可进一步提供。
**Background of ATAD2 Antibody**
ATAD2 (ATPase family AAA domain-containing protein 2), also known as ANCCA or PRO2000. is a chromatin-associated protein implicated in transcriptional regulation, DNA replication, and cancer progression. It contains an AAA+ ATPase domain and a bromodomain, enabling its role in chromatin remodeling and interaction with acetylated histones or transcription factors. ATAD2 is overexpressed in various cancers, including breast, prostate, ovarian, and lung cancers, where it correlates with poor prognosis, tumor aggressiveness, and therapeutic resistance.
Functionally, ATAD2 acts as a co-activator for oncogenic transcription factors like MYC and estrogen receptor-alpha (ERα), promoting cell proliferation, survival, and metastasis. It also participates in DNA replication by facilitating the assembly of replication complexes. Due to its cancer-specific overexpression and critical roles in oncogenesis, ATAD2 is studied as a potential biomarker and therapeutic target.
ATAD2 antibodies are essential tools for detecting ATAD2 expression in research and diagnostics. They are used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study ATAD2 localization, expression levels, and interactions in cancer models. Monoclonal and polyclonal antibodies targeting specific domains (e.g., bromodomain) help dissect its molecular mechanisms. Validated antibodies with high specificity are crucial, as cross-reactivity with homologous proteins (e.g., ATAD2B) may occur. Recent studies also explore ATAD2 inhibitors, underscoring the antibody's utility in preclinical drug development.
×
